Journal: Nature Communications

Article Title: Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats

doi: 10.1038/s41467-025-63553-5

Figure Lengend Snippet: a Synthetic route of pB-UC18. b Representative TEM image (Scale bar, 500 nm) as well as D H , PDI, and ζ of pB-UC18 LNPs determined by dynamic light scattering. c Hemolytic activity of pB-UC18 LNPs at pH 7.4 and 5.4. d Colocalization analysis of the endosomal escape capacity of pB-UC18 LNPs encapsulating Cy5-labeled mRNA (red). The endo-lysosomes were specifically stained with green dyes. Scale bar, 50 μm. e Effects of different chemical inhibitors of endocytosis on the internalization of pB-UC18 LNPs. The mean fluorescence intensity (MFI) of the no-inhibitor control was defined as 100%. Data are presented as mean ± SEM ( n = 3 biological replicates, one-way ANOVA with Dunnett’s multiple comparison test). f Immunofluorescence images of cells treated with hLSS mRNA-loaded pB-UC18 LNPs for 24 h. Green, LSS proteins. Scale bar, 50 μm. g Western blot analysis of the expression level of LSS proteins from cells treated with hLSS mRNA-loaded pB-UC18 LNPs or PBS for 24 h. Endogenous β -actin was used as a loading control. h Quantification of the relative intensity of LSS protein expression from g . Data are presented as mean ± SEM ( n = 3 biological replicates, unpaired, two-tailed Student’s t test). Source data are provided as a Source Data file.

Article Snippet: FLuc mRNA-loaded SM-102 LNPs prepared at a SM-102:FLuc mRNA weight ratio of 10.75:1 and a SM-102 (Macklin):DSPC (Avanti):cholesterol (Sangon Biotech):DMG-PEG2k (TargetMol) molar ratio of 50:10:38.5:1.5 were used as a positive control .

Techniques: Activity Assay, Labeling, Staining, Fluorescence, Control, Comparison, Immunofluorescence, Western Blot, Expressing, Two Tailed Test

Journal: Nature Communications

Article Title: Ocular delivery of lipid nanoparticles-formulated mRNA encoding lanosterol synthase ameliorates cataract in rats

doi: 10.1038/s41467-025-63553-5

Figure Lengend Snippet: a Representative whole-body bioluminescence images of Wistar rats at different times after IVT, SCJ, IC, or SR injection of FLuc mRNA-loaded pB-UC18 LNPs (300 ng FLuc mRNA per injection). b Ex vivo bioluminescence images of the ocular tissues from a . Le, lens. EW, eyeball wall. Co, cornea. EW-Co, eyeball wall without cornea. Dashed lines indicated the border between two images. Following 4 h whole-body bioluminescence imaging, 2 out of 4 rats from each group were sacrificed for ex vivo imaging. The remaining 2 rats were subjected to whole-body bioluminescence imaging repeatedly over time (26 h and 48 h) and sacrificed at 48 h for ex vivo imaging. c , d Quantification of luminescence flux in eyes ( c ) and lenses ( d ), which were from a and b (48 h), respectively. Dashed lines in ( c ) indicated the background flux in the eyes. BG-Le in ( d ) indicated the background flux in the lenses. e Representative whole-body bioluminescence images of Wistar rats 4 h after IC injection of FLuc mRNA-loaded pB-UC18 LNPs at different mRNA doses. Uninjected rats and rats injected with SM-102 LNPs at a FLuc mRNA dose of 200 ng served as control groups. f Quantification of luminescence flux in the eyes from e ( n = 4 rats for 0 ng and 200 ng; n = 3 rats for 40 ng and 120 ng; one-way ANOVA with Sidak’s multiple comparison test). For all relevant panels, data are presented as mean ± SEM. Source data are provided as a Source Data file.

Article Snippet: FLuc mRNA-loaded SM-102 LNPs prepared at a SM-102:FLuc mRNA weight ratio of 10.75:1 and a SM-102 (Macklin):DSPC (Avanti):cholesterol (Sangon Biotech):DMG-PEG2k (TargetMol) molar ratio of 50:10:38.5:1.5 were used as a positive control .

Techniques: Injection, Ex Vivo, Imaging, Control, Comparison